The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation for opioid use disorder and speed up availability of treatment ...

Indivior (INDV) announced that the FDA has approved label changes for Sublocade including a rapid initiation protocol and alternative injection sites, marking a significant advancement in the ...

SUBLOCADE’s 2025 revenue is forecasted at $725M to $765M, assuming stabilization of competitive dynamics and incremental growth in organized health systems. OPVEE is expected to generate $10M to ...